Stay informed with QuickTake’s coronavirus coverage of up-to-the-minute stories on the COVID-19 crisis. #Coronavirus #Covid19 #CoronavirusUpdates
Moderna Inc.’s Covid-19 vaccine produced antibodies to the coronavirus in all patients tested in an initial safety trial, federal researchers said, clearing an important milestone as the U.S. continues to grapple with a surge in new infections.
The findings are likely to increase hopes that a vaccine can be brought to market quickly. However, a number of patients in the trial experienced side effects, some of them severe. The vaccine will move into a much larger late-stage trial later this month that’s likely to determine whether it’s approved by U.S. regulators.
The neutralizing antibody levels in the trial produced were equivalent to the upper half of what’s seen in patients who get infected with the virus and recover, according to the results published Tuesday in the New England Journal of Medicine.
Covid-19 deaths among Florida residents rose by a record 132, another sign that the virus’s resurgence across the Sun Belt is starting to have severe consequences.
The fatalities rose 3.1% to 4,409 cumulatively, according to a report Tuesday, which includes data through Monday. On a rolling seven-day basis, Florida has reported 568 new coronavirus fatalities, also a record.
Florida reported 291,629 Covid-19 cases on Tuesday, up 3.3% from a day earlier, compared with an average increase of 4.6% in the previous seven days. Cumulative hospitalizations of Florida residents rose by 383, or 2.1%, to 18,881. On a rolling seven-day basis, hospitalizations have totaled 2,456, another record.
Subscribe to our YouTube channel:
QUICKTAKE ON SOCIAL:
Follow QuickTake on Twitter: twitter.com/quicktake
Like QuickTake on Facebook: facebook.com/quicktake
Follow QuickTake on Instagram: instagram.com/quicktake
Subscribe to our newsletter:
Email us at email@example.com
QuickTake by Bloomberg is a global news network delivering up-to-the-minute analysis on the biggest news, trends and ideas for a new generation of leaders.